Parathyroid Cancer

Surgical Oncology Clinics of North America

Volumn 15, Issue 3, 2006, Pages 573-584

  Lang, Brian ^a   Lo, Chung Yau ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITONIN; CINACALCET; FUROSEMIDE; ITRACONAZOLE; KETOCONAZOLE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARATHYROID HORMONE; STEROID; VINBLASTINE;

BENIGN TUMOR; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ECTOPIC HORMONE PRODUCTION; FLUID THERAPY; GENE MUTATION; HEMODIALYSIS; HORMONE DETERMINATION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOCALCEMIA; INTRAOPERATIVE PERIOD; NAUSEA AND VOMITING; NECK TUMOR; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARATHYROID CARCINOMA; REVIEW; SCINTIGRAPHY; URINARY EXCRETION;

HUMANS; HYPERCALCEMIA; INTRAOPERATIVE PERIOD; NAPHTHALENES; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; PARATHYROIDECTOMY; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI;

EID: 33746352806     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2006.05.003     Document Type: Review

References (75)

1. Hundahl S.A., Fleming I.D., Fremgen A.M., et al. Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985-1995: a National Cancer Data Base report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 86 3 (1999) 538-544
2. Shane E. Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab 86 2 (2001) 485-493
3. Lo C.Y., Chan W.F., Kung A.W.C., et al. Surgical treatment for primary hyperparathyroidism in Hong Kong: changes in clinical pattern over 3 decades. Arch Surg 139 1 (2004) 77-82
4. Obara T., and Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg 15 6 (1991) 738-744
5. Favia G., Lumachi F., Polistina F., et al. Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World J Surg 22 12 (1998) 1225-1230
6. Mishra S.K., Agarwal G., Kar D.K., et al. Unique clinical characteristics of primary hyperparathyroidism in India. Br J Surg 88 5 (2001) 708-714
7. Rao S.R., Shaha A.R., Singh B., et al. Management of cancer of the parathyroid. Acta Otolaryngol 122 4 (2002) 448-452
8. Beus K.S., and Stack Jr. B.C. Parathyroid carcinoma. Otolaryngol Clin North Am 37 4 (2004) 845-854
9. Mittendorf E.A., and McHenry C.R. Parathyroid carcinoma. J Surg Oncol 89 3 (2005) 136-142
10. Koea J.B., and Shaw J.H. Parathyroid cancer: biology and management. Surg Oncol 8 3 (1999) 155-165
11. Kirkby-Bott J., Lewis P., Harmer C.L., et al. One stage treatment of parathyroid cancer. Eur J Sur Oncol 31 1 (2005) 78-83
12. Hamill J., Maoate K., Beasley S.W., et al. Familial parathyroid carcinoma in a child. J Paediatr Child Health 38 3 (2002) 314-317
13. Christmas T.J., Chapple C.R., Nobel J.G., et al. Hyperparathyroidism after neck irradiation. Br J Surg 75 9 (1988) 873-874
14. Miki H., Sumitomo M., Inoue H., et al. Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. Surgery 120 5 (1996) 897-901
15. Wassif W.S., Moniz C.F., Friedman E., et al. Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab 77 6 (1993) 1485-1489
16. Marx S.J., Simonds W.F., Agarwal S.K., et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res 17 Suppl 2 (2002) N37-N43
17. Carpten J.D., Robbins C.M., Villablanca A., et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32 4 (2002) 676-680
18. Weinstein L.S., and Simonds W.F. HRPT2, a marker of parathyroid cancer. N Engl J Med 349 18 (2003) 1691-1692
19. Wynne A.G., van Heerden J., Carney J.A., et al. Parathyroid carcinoma: clinical and pathological features in 43 patients. Medicine (Baltimore) 71 4 (1992) 197-205
20. Robert J.H., Trombetti A., Garcia A., et al. Primary hyperparathyroidism: can parathyroid carcinoma be anticipated on clinical and biochemical grounds? Report of nine cases and review of the literature. Ann Surg Oncol 12 7 (2005) 526-532
21. Holmes E.C., Morton D.L., and Ketcham A.S. Parathyroid carcinoma: a collective review. Ann Surg 169 4 (1969) 631-640
22. Kebebew E. Parathyroid carcinoma. Curr Treat Options Oncol 2 4 (2001) 347-354
23. Kebebew E., and Clark O.H. Parathyroid adenoma, hyperplasia and carcinoma: localization, technical details of primary neck exploration, and treatment of hypercalcemic crisis. Surg Oncol Clin N Am 7 4 (1998) 721-748
24. Fleischer J., Becker C., Hamele-Bena D., et al. Oxyphil parathyroid adenoma: a malignant presentation of a benign disease. J Clin Endocrinol Metab 89 12 (2004) 5948-5951
25. Kleinpeter K.P., Lovato J.F., Clark P.B., et al. Is parathyroid carcinoma indeed a lethal disease?. Ann Surg Oncol 12 3 (2005) 260-266
26. Spinelli C., Bonadio A.G., Berti P., et al. Cutaneous spreading of parathyroid carcinoma after fine needle aspiration cytology. J Endocrinol Invest 23 4 (2000) 255-257
27. Thompson S.D., and Prichard A.J. The management of parathyroid carcinoma. Cur Opin Otolaryngol Head Neck Surg 12 2 (2004) 93-97
28. DeLellis R.A. Parathyroid carcinoma: an overview. Adv Anat Pathol 12 2 (2005) 53-61
29. Schantz A., and Castleman B. Parathyroid carcinoma: a study of 70 cases. Cancer 31 3 (1973) 600-605
30. Kameyama K., and Takami H. Proposal for the histological classification of parathyroid carcinoma. Endocr Pathol 6 1 (2005) 49-52
31. Apel R.L., and Asa S.L. The parathyroid glands. In: LiVolsi V.A., and Asa S.L. (Eds). Endocrine pathology (2002), Churchill Livingstone, New York 103-147
32. Krebs L.J., Shattuck T.M., and Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 90 9 (2005) 5015-5017
33. Rubin M.R., and Silverberg S.J. HRPT2 in parathyroid cancer: a piece of the puzzle. [editorial]. J Clin Endocrinol Metab 90 9 (2005) 5505-5507
34. Shattuck T., Valimaki S., Obara T., et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349 18 (2003) 1722-1729
35. Senior K. Vital gene linked to parathyroid carcinoma. Lancet Oncol 4 12 (2003) 713
36. Teh B.T., Farnebo F., Kristoffersson U., et al. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal harmatomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal harmartomas. J Clin Endocrinol Metab 81 12 (1996) 4204-4211
37. Teh B.T., Farnebo F., Twigg S., et al. Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families. J Clin Endocrinol Metab 83 6 (1998) 2114-2120
38. Cavaco B.M., Guerra L., Bradley K.J., et al. Hyperparathyroidism-jaw tumor syndrome in Roma families from Portugal is due to a founder mutation of the HRPT2 gene. J Clin Endocrinol Metab 89 4 (2004) 1747-1752
39. Howell V.M., Haven C.J., and Kahnoski K. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 40 9 (2003) 657-663
40. Rawat N., Khetan N., Williams D.W., et al. Parathyroid carcinoma. Br J Surg 92 11 (2005) 1345-1353
41. Koo W.S., Jeon D.S., Ahn S.J., et al. Calcium-free hemodialysis for the management of hypercalcemia. Nephron 72 3 (1996) 424-428
42. Ariyan C.E., and Sosa J.A. Assessment and management of patients with abnormal calcium. Crit Care Med 32 4 Suppl (2004) S146-S154
43. Lee J.A., and Inabnet III W.B. The surgeon's armamentarium to the surgical treatment of primary hyperparathyroidism. J Surg Oncol 89 3 (2005) 130-135
44. Kameyama K., and Takami H. Double parathyroid carcinoma. Endocr J 50 4 (2003) 477-479
45. Khati N., Adamson T., Johnson K.S., et al. Ultrasound of the thyroid and parathyroid glands. Ultrasound Q 19 4 (2003) 162-176
46. Hara H., Igarashi A., Yano Y., et al. Ultrasonographic features of parathyroid carcinoma. Endocr J 48 2 (2001) 213-217
47. Tamler R., Lewis M.S., LiVolsi V.A., et al. Parathyroid carcinoma: ultrasonographic and histologic features. Thyroid 15 7 (2005) 744-745
48. Slater A., and Gleeson F.V. Increased sensitivity and confidence of SPECT over planar imaging in dual-phase sestamibi for parathyroid adenoma detection. Clin Nucl Med 30 1 (2005) 1-3
49. Smith J.R., and Oates M.E. Radionuclide imaging of the parathyroid glands: patterns, pearls, and pitfalls. Radiographics 24 4 (2004) 1101-1115
50. Clark P., Wooldridge T., Kleinpeter K., et al. Providing optimal preoperative localization for recurrent parathyroid carcinoma: a combined parathyroid scintigraphy and computed tomography approach. Clin Nucl Med 29 11 (2004) 681-684
51. Kebebew E., Arici C., Duh Q.Y., et al. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 136 8 (2001) 878-885
52. Aso Y., Sato A., Tayama K., et al. Parathyroid carcinoma with metastatic calcification identified by technetium-99m methylene diphosphonate scintigraphy. Intern Med 35 5 (1996) 392-395
53. Al-Sobhi S., Ashari L., and Ingemansson S. Detection of metastatic parathyroid carcinoma with Tc-99m sestamibi imaging. Clin Nucl Med 24 1 (1999) 21-23
54. Iacobone M., Lumachi F., and Favia G. Up-to-date on parathyroid carcinoma: analysis of an experience of 19 cases. J Surg Oncol 88 4 (2004) 223-228
55. Chen H., Mack E., and Starling J.R. A comprehensive evaluation of perioperative adjuncts during minimally invasive parathyroidectomy: which is most reliable?. Ann Surg 242 3 (2005) 375-383
56. Jaskowiak N.T., Sugg S.L., Helke J., et al. Pitfalls of intraoperative quick parathyroid hormone monitoring and gamma probe localization in surgery for primary hyperparathyroidism. Arch Surg 137 6 (2002) 659-669
57. Inabnet III W.B., Kim C.K., Haber R.S., et al. Radioguidance is not necessary during parathyroidectomy. Arch Surg 137 8 (2002) 967-970
58. Shaha A.R., Patel S.G., and Singh B. Minimally invasive parathyroidectomy: the role of radio-guided surgery. Laryngoscope 112 12 (2002) 2166-2169
59. Murphy C., and Norman J. The 20% rule: a simple, instantaneous radioactivity measurement defines cure and allows elimination of frozen sections and hormone assays during parathyroidectomy. Surgery 126 6 (1999) 1023-1029
60. Norman J.G., Jaffray C.E., and Chheda H. The false-positive parathyroid sestamibi: a real or perceived problem and a case for radioguided parathyroidectomy. Ann Surg 231 1 (2000) 31-37
61. Chen H., Pruhs Z., Starling J.R., et al. Intraoperative parathyroid hormone testing improves cure rates in patients undergoing minimally invasive parathyroidectomy. Surgery 138 4 (2005) 583-590
62. Weber K.J., Misra S., Lee J.K., et al. Intraoperative PTH monitoring in parathyroid hyperplasia requires stricter criteria for success. Surgery 136 6 (2004) 1154-1159
63. Clayman G.L., Gonzalez H.E., El-Nagger A., et al. Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer 100 5 (2004) 900-905
64. Sandelin K., Auer G., Bondeson L., et al. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg 16 4 (1992) 724-731
65. Doherty G. Parathyroid glands. In: Greenfield L.J., Mulholland M.W., Oldham K.T., et al. (Eds). Surgery: scientific principles and practice. 3rd edition (2001), Lippincott Williams & Wilkins, New York 1284-1306
66. Obara T., Okamoto T., Kanbe M., et al. Functioning parathyroid carcinoma: clinicopathologic features and rational treatment. Semin Surg Oncol 13 2 (1997) 134-141
67. Munson N.D., Foote R.L., Northcutt R.C., et al. Parathyroid carcinoma: is there a role for adjuvant radiation therapy?. Cancer 98 11 (2003) 2378-2384
68. Block G.A., Martin K.J., de Francisco A.L., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350 15 (2004) 1516-1525
69. Lindberg J.S., Moe S.M., Goodman W.G., et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 63 1 (2003) 248-254
70. Quarles L.D., Sherrard D.J., Adler S., et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14 3 (2003) 575-583
71. Collins M.T., Skarulis M.C., Bilezikian J.P., et al. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83 4 (1998) 1083-1088
72. Dong D.B. Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther 27 11 (2005) 1725-1751
73. Poon G. Cinacalcet hydrochloride (Sensipar). Proc Bayl Univ Med Center 18 2 (2005) 181-184
74. Silverberg S.J., Fairman C., Bilezikian J.P., et al. The effects of cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary HPT after PTX. J Bone Miner Res 18 Suppl 2 (2003) S171 [Abstract SA-420]
75. Silverberg S.J., Fairman C., Bilezikian J.P., et al. Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma. J Bone Miner Res 19 Suppl 1 (2004) S103 [Abstract SA-495]